May 7, 2018 / 5:30 AM / 6 months ago

BRIEF-Genkyotex Announces SMB's Positive Review Of GKT831 Phase 2 Trial In Primary Biliary Cholangitis

May 7 (Reuters) - GenKyoTex SA:

* GENKYOTEX ANNOUNCES POSITIVE OUTCOME FROM INDEPENDENT SMB’S FIRST PRE-PLANNED REVIEW OF GKT831’S PHASE 2 TRIAL IN PRIMARY BILIARY CHOLANGITIS

* RESULTS OF INTERIM EFFICACY ANALYSIS FROM PHASE 2 TRIAL EXPECTED TO BE AVAILABLE IN FALL 2018

* A TOTAL OF 102 PBC PATIENTS WILL BE ENROLLED AND ALLOCATED TO PLACEBO OR ONE OF TWO DOSES OF GKT831

* SMB RECOMMENDED CONTINUATION OF STUDY AS PER PROTOCOL, WITH NO CHANGES OR ADDITIONAL DATA COLLECTION REQUIRED Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below